Empagliflozin
Ki inhibiting AChE is 0.177 microM. Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney.highest selectivity for SGLT2 over SGLT1
General
Type : Drug, Multitarget, Sodium-glucose cotransporter 2, Glycoside
Chemical_Nomenclature : (2S,3R,4R,5S,6R)-2-[4-chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
Canonical SMILES : C1COC[C@H]1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)Cl
InChI : InChI=1S\/C23H27ClO7\/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17\/h1-6,10,17,19-23,25-28H,7-9,11-12H2\/t17-,19+,20+,21-,22+,23-\/m0\/s1
InChIKey : OBWASQILIWPZMG-QZMOQZSNSA-N
Other name(s) : Jardiance || BI 10773 || BI10773 || BI-10773 || Empagliflozina || Empagliflozine
MW : 450.9
Formula : C23H27ClO7
CAS_number : 864070-44-0
PubChem : 11949646
UniChem : OBWASQILIWPZMG-QZMOQZSNSA-N
Target
References (6)
| Title : Neuroprotective effects of empagliflozin against scopolamine-induced memory impairment and oxidative stress in rats - Anoush_2025_IBRO.Neurosci.Rep_18_163 |
| Author(s) : Anoush M , Taghaddosi N , Bokaei Hosseini Z , Rahmati F , Bijani S , Kalantari-Hesari A , Hosseini MJ |
| Ref : IBRO Neurosci Rep , 18 :163 , 2025 |
| Abstract : |
| PubMedSearch : Anoush_2025_IBRO.Neurosci.Rep_18_163 |
| PubMedID: 39896712 |
| Title : Sodium-dependent Glucose Co-Transporter-2 Inhibitor Empagliflozin Exerts Neuroprotective Effects in Rotenone-Induced Parkinson's Disease Model in Zebrafish\; Mechanism Involving Ketogenesis and Autophagy - Unal_2023_Brain.Res__148536 |
| Author(s) : Unal I , Cansiz D , Beler M , Sezer Z , Guzel E , Emekli-Alturfan E |
| Ref : Brain Research , :148536 , 2023 |
| Abstract : |
| PubMedSearch : Unal_2023_Brain.Res__148536 |
| PubMedID: 37591458 |
| Title : SGLT2 and DPP4 inhibitors improve Alzheimer's disease-like pathology and cognitive function through distinct mechanisms in a T2D-AD mouse model - Sim_2023_Biomed.Pharmacother_168_115755 |
| Author(s) : Sim AY , Choi DH , Kim JY , Kim ER , Goh AR , Lee YH , Lee JE |
| Ref : Biomed Pharmacother , 168 :115755 , 2023 |
| Abstract : |
| PubMedSearch : Sim_2023_Biomed.Pharmacother_168_115755 |
| PubMedID: 37871560 |
| Title : Perspective of SGLT2 Inhibition in Treatment of Conditions Connected to Neuronal Loss: Focus on Alzheimer's Disease and Ischemia-Related Brain Injury - Wicinski_2020_Pharmaceuticals.(Basel)_13_ |
| Author(s) : Wicinski M , Wodkiewicz E , Gorski K , Walczak M , Malinowski B |
| Ref : Pharmaceuticals (Basel) , 13 : , 2020 |
| Abstract : |
| PubMedSearch : Wicinski_2020_Pharmaceuticals.(Basel)_13_ |
| PubMedID: 33187206 |
| Title : Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes - Jojima_2016_Diabetol.Metab.Syndr_8_45 |
| Author(s) : Jojima T , Tomotsune T , Iijima T , Akimoto K , Suzuki K , Aso Y |
| Ref : Diabetol Metab Syndr , 8 :45 , 2016 |
| Abstract : |
| PubMedSearch : Jojima_2016_Diabetol.Metab.Syndr_8_45 |
| PubMedID: 27462372 |
| Title : Prediction of Anti-Diabetic Drugs as Dual Inhibitors Against Acetylcholinesterase and Beta-Secretase: A Neuroinformatics Study - Shaikh_2016_CNS.Neurol.Disord.Drug.Targets_15_1216 |
| Author(s) : Shaikh S , Rizvi SM , Suhail T , Shakil S , Abuzenadah AM , Anis R , Naaz D , Dallol A , Haneef M , Ahmad A , Choudhary L |
| Ref : CNS Neurol Disord Drug Targets , 15 :1216 , 2016 |
| Abstract : |
| PubMedSearch : Shaikh_2016_CNS.Neurol.Disord.Drug.Targets_15_1216 |
| PubMedID: 27697060 |